[1] |
Bureau of Medical AdministrationNational Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
|
[2] |
LEE WC, JENG LB, CHEN MF. Estimation of prognosis after hepatectomy for hepatocellular carcinoma[J]. Br J Surg, 2002, 89(3): 311-316. DOI: 10.1046/j.0007-1323.2001.02034.x.
|
[3] |
Bureau of Medical Administration National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
中华人民共和国国家卫生健康委员会医政医管局. 原发性肝癌诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2020, 36(2): 277-292. DOI: 10.3969/j.issn.1001-5256.2020.02.007.
|
[4] |
TOSHIMORI J, NOUSO K, NAKAMURA S, et al. Local recurrence and complications after percutaneous radiofrequency ablation of hepatocellular carcinoma: A retrospective cohort study focused on tumor location[J]. Acta Med Okayama, 2015, 69(4): 219-226. DOI: 10.18926/AMO/53558.
|
[5] |
LEE CH, CHEN WT, LIN CC, et al. Radiofrequency ablation assisted by real-time virtual sonography for hepatocellular carcinoma inconspicuous under sonography and high-risk locations[J]. Kaohsiung J Med Sci, 2015, 31(8): 413-419. DOI: 10.1016/j.kjms.2015.06.002.
|
[6] |
NAKAZAWA T, KOKUBU S, SHIBUYA A, et al. Radiofrequency ablation of hepatocellular carcinoma: Correlation between local tumor progression after ablation and ablative margin[J]. AJR Am J Roentgenol, 2007, 188(2): 480-488. DOI: 10.2214/AJR.05.2079.
|
[7] |
JIANG C, LIU B, CHEN S, et al. Safety margin after radiofrequency ablation of hepatocellular carcinoma: Precise assessment with a three-dimensional reconstruction technique using CT imaging[J]. Int J Hyperthermia, 2018, 34(8): 1135-1141. DOI: 10.1080/02656736.2017.1411981.
|
[8] |
Chinese Society of Liver Cancer, Chinese Anti-Cancer Association; Chinese Society of Clinical Oncology, Chinese Anti-Cancer Association; Liver Cancer Study Group, Chinese Society of Hepatology, Chinese Medical Association. Expert consensus on the norms of local ablation therapy for hepatocellular carcinoma[J]. J Clin Hepatol, 2011, 27(3): 236-238, 244. http://lcgdbzz.org/article/id/LCGD201103004
中国抗癌协会肝癌专业委员会, 中国抗癌协会临床肿瘤学协作专业委员会, 中华医学会肝病学分会肝癌学组. 肝癌局部消融治疗规范的专家共识[J]. 临床肝胆病杂志, 2011, 27(3): 236-238, 244. http://lcgdbzz.org/article/id/LCGD201103004
|
[9] |
LENCIONI R, LLOVET JM. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma[J]. Semin Liver Dis, 2010, 30(1): 52-60. DOI: 10.1055/s-0030-1247132.
|
[10] |
BENSON AB 3rd, D'ANGELICA MI, ABBOTT DE, et al. NCCN guidelines insights: Hepatobiliary cancers, version 1.2017[J]. J Natl Compr Canc Netw, 2017, 15(5): 563-573. DOI: 10.6004/jnccn.2017.0059.
|
[11] |
ZHU P, WANG YM. Updated key points and clinical pathway for NCCN clinical practice guidelines in oncology: Hepatobiliary cancers (Version2. 2016)[J]. J Clin Hepatol, 2016, 32(9): 1644-1652. DOI: 10.3969/j.issn.1001-5256.2016.09.003.
朱鹏, 王宇明. 《2016年美国国立综合癌症网络肝胆肿瘤临床实践指南(V2版)》更新要点及临床路径[J]. 临床肝胆病杂志, 2016, 32(9): 1644-1652. DOI: 10.3969/j.issn.1001-5256.2016.09.003.
|
[12] |
YANG BS, YUAN M, HOU YB, et al. TACE combined with precision radiofrequency ablation by using multiple imaging guidance technology for HCC located at exceptionalsites[J]. J Intervent Radiol, 2018, 27(12): 1193-1198. DOI: 10.3969/j.issn.1008-794X.2018.12.018.
杨柏帅, 袁敏, 侯毅斌, 等. TACE联合多影像引导技术精准消融特殊部位肝细胞癌29例[J]. 介入放射学杂志, 2018, 27(12): 1193-1198. DOI: 10.3969/j.issn.1008-794X.2018.12.018.
|
[13] |
HAN HY, JING X, DING JM, et al. Safety and efficacy of microwave ablation for hepatocellular carcinoma at dangerous locations[J]. Chin J Interv Imaging Ther, 2017, 14(4): 205-209. DOI: 10.13929/j.1672-8475.201611009.
韩海云, 经翔, 丁建民, 等. 经皮微波消融治疗危险部位肝癌的安全性和疗效分析[J]. 中国介入影像与治疗学, 2017, 14(4): 205-209. DOI: 10.13929/j.1672-8475.201611009.
|
[14] |
TERATANI T, YOSHIDA H, SHⅡNA S, et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations[J]. Hepatology, 2006, 43(5): 1101-1108. DOI: 10.1002/hep.21164.
|
[15] |
HUANG H, LIANG P, YU XL, et al. Safety assessment and therapeutic efficacy of percutaneous microwave ablation therapy combined with percutaneous ethanol injection for hepatocellular carcinoma adjacent to the gallbladder[J]. Int J Hyperthermia, 2015, 31(1): 40-47. DOI: 10.3109/02656736.2014.999017.
|
[16] |
ZHANG M, LIANG P, CHENG ZG, et al. Efficacy and safety of artificial ascites in assisting percutaneous microwave ablation of hepatic tumours adjacent to the gastrointestinal tract[J]. Int J Hyperthermia, 2014, 30(2): 134-141. DOI: 10.3109/02656736.2014.891765.
|
[17] |
WONG SN, LIN CJ, LIN CC, et al. Combined percutaneous radiofrequency ablation and ethanol injection for hepatocellular carcinoma in high-risk locations[J]. AJR Am J Roentgenol, 2008, 190(3): w187-w195. DOI: 10.2214/AJR.07.2537.
|
[18] |
LIU A, XU W, XU H, et al. Effects of ultrasound-guided low-power microwave ablation for the treatment of liver cancer in special sites[J]. J Pract Radiol, 2018, 34(12): 1925-1928. DOI: 10.3969/j.issn.1002-1671.2018.12.028.
柳昂, 许伟, 徐浩, 等. 超声引导下小功率微波消融术治疗特殊部位肝癌疗效分析[J]. 实用放射学杂志, 2018, 34(12): 1925-1928. DOI: 10.3969/j.issn.1002-1671.2018.12.028.
|
[19] |
ZHANG NN, CHENG XJ, LIU JY, et al. High-powered microwave ablation in treating patients with hepatocellular carcinoma and the risk fac-tors of recurrence[J]. J Prac Hepatol, 2015, 18(3): 249-253. DOI: 10.3969/j.issn.1672-5069.2015.02.008.
张宁宁, 程晓静, 刘建勇, 等. 大功率微波消融治疗肝癌临床疗效及其复发危险因素分析[J]. 实用肝脏病杂志, 2015, 18(3): 249-253. DOI: 10.3969/j.issn.1672-5069.2015.02.008.
|